Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
35.7 HKD | +2.29% | +22.47% | -27.29% |
04:41am | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.29% | 1.23B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%